Insmed to Participate at the UBS Global Healthcare Conference
11 Mai 2015 - 2:41PM
Business Wire
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on developing orphan treatments for rare pulmonary
diseases, today announced that company management will participate
at the 2015 UBS Global Healthcare conference taking place at the
Sheraton New York Times Square Hotel from May 18 to May 20. Will
Lewis, president and chief executive officer of Insmed, will
participate in an analyst-led fireside chat on Monday, May 18 at
4:00 PM ET.
Mr. Lewis’ presentation will be webcast live and can be accessed
by visiting the investor section of the company’s website at
www.insmed.com. The webcast will be archived for a period of 90
days following the live webcast.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious lung diseases.
Insmed is focused on the development and commercialization of
ARIKAYCE™, or liposomal amikacin for inhalation, for at least two
identified orphan patient populations: patients with nontuberculous
mycobacteria (NTM) lung infections and cystic fibrosis (CF)
patients with Pseudomonas aeruginosa lung infections. Insmed is
also focused on the development of INS1009, the company’s inhaled
treprostinil prodrug for the treatment of pulmonary arterial
hypertension (PAH), a chronic, life-threatening disorder
characterized by abnormally high blood pressure in the arteries
between the heart and lungs.
Insmed Incorporated:Susan Mesco, 908-947-4326Head of
Investor Relations
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024